血清肿瘤标志物检测在肺癌诊断与临床分期中的应用
2020-10-21吴秀花
吴秀花

【摘 要】目的:分析研究血清肿瘤标志物检测在肺癌诊断与临床分期中的应用价值。方法:取2017.03~2019.07时段接收68例肺癌患者作为观察组,同期体检68例作为对照组,均采用免疫化学发光法检测肿瘤标志物,对比肿瘤标志物水平。结果:分析肿瘤标志物水平,结果显示,观察组SCC水平为(2.31±2.1)ng/ml、CEA水平为(29.7±8.61)ng/ml、NSE水平为(24.28±2.3)ng/ml、CA125Ⅱ水平为(36.85±7.52)U/ml以及CYFRA21-1水平为(13.49±4.52)ng/ml,观察组肿瘤标志物水平较对照组更高,对比差异显著,P<0.05。结论:实施血清肿瘤标志物检测方法,对肺癌患者具有准确判断病情的效果,在肺癌诊断过程中价值较高,在临床中值得应用和推广。
【关键词】血清肿瘤标志物;肺癌诊断;应用价值
【中图分类号】R734.2 【文献标识码】A 【文章编号】1002-8714(2020)05-0008-02
【Abstract】Objective: to analyze the value of serum tumor markers in the diagnosis and clinical stage of lung cancer. Methods: from March 2017 to July 2019, 68 lung cancer patients were taken as the observation group and 68 physical examination patients were taken as the control group. Results: the level of tumor markers in the observation group was (2.31 ± 2.1) ng / ml, CEA was (29.7 ± 8.61) ng / ml, NSE was (24.28 ± 2.3) ng / ml, CA125 Ⅱ was (36.85 ± 7.52) U / ml and CYFRA21-1 was (13.49 ± 4.52) ng / ml. the level of tumor markers in the observation group was higher than that in the control group, with significant difference (P < 0.05). Conclusion: the detection method of serum tumor markers has the effect of accurately judging the condition of patients with lung cancer. It has high value in the diagnosis of lung cancer and is worthy of application and promotion in clinical practice.
【Key words】serum tumor markers; lung cancer diagnosis; application value
在临床中,肺癌是常见疾病,发病率和死亡率较高,给患者带来较大的生理痛苦和经济负担。一般情况下,利用影像学对肺癌患者进行检查和诊断,患者在发病初期难以确诊,错过最佳治疗时机[1]。血清肿瘤标志物属于特异性物质,在患者发病早期,检测血清肿瘤标志物,能够有效进行诊断,且具有操作简便、费用低的优势,应用范围比较广泛。本文择取2017.03~2019.07时段接收68例肺癌患者,观察血清肿瘤标志物检测在肺癌诊断与临床分期中的应用价值,现有以下内容。
1 资料与方法
1.1 一般资料
时段:2017.03~2019.07,择取科室诊疗的68例肺癌患者作为观察组,同期体检68例作为对照组,均采用免疫化学发光法检测肿瘤标志物,对照组33例女性,35例男性,年龄54~83岁,均值为(68.36±7.22)岁,病程为0.5~1年,均值为(0.75±0.04)年。观察组32例女性,36例男性,年龄55~82岁,均值为(69.03±7.15)岁,病程为0.6~1.5年,均值为(1.11±0.01)年。对比一般资料,无差异性,P>0.05。
1.2 方法
抽取68例肺癌患者和68例体检人员空腹静脉血5ml,然后将其放置在温室,放置30min后提取血清,在-80度的环境中放置血清,利用AUTOAE2100磁微粒全自动化学发光仪检测SCC和CYFRA21-1,利用電化学发光法检测其他肿瘤标志物[2]。在……
